Credo's Margin Guidance Overshadows Robust Q3 Growth

What happened

Credo reported strong Q3 FY2026 results with $407 million revenue, up 200% year-over-year, and gross margins around 68.6%, driven by hyperscaler demand. Despite this performance, the stock fell approximately 21% due to management's guidance for Q4 gross margins to compress to 64-66%, signaling normalization from peak levels. This margin pressure stems from product mix shifts and competitive dynamics, not a fundamental weakening in demand, as highlighted in the Seeking Alpha article. The DeepValue report warns that Credo's high valuation—with a P/E of 60.7x—already discounts sustained growth, making margin stability and inventory discipline critical sensitivities. Investors are now focused on whether Credo can deliver Q4 revenue within its $425-$435 million guide while avoiding risks like inventory write-downs from its $90 million inventory base.

Implication

The margin guidance compression reveals Credo's vulnerability to pricing and mix volatility, challenging its ability to maintain the profitability levels priced into the stock. With elevated valuation multiples, any miss on Q4 revenue or gross margin below 64% could trigger significant downside, given the crowded AI narrative and high investor expectations. Inventory risks are material, as the $90 million inventory base is demand-sensitive and prone to write-downs if hyperscaler deployment pacing slows, compounding operational pressures. Credo's long-term growth depends on roadmap execution, particularly PCIe Gen6 AEC mass production by 1H FY2027, but delays could undermine competitive positioning. Therefore, prudent investors should monitor the next quarterly report for adherence to guidance and inventory metrics, maintaining a cautious stance until these uncertainties resolve.

Thesis delta

The article confirms the margin compression risk highlighted in the DeepValue report, reinforcing that stock volatility is tightly linked to guidance nuances rather than absolute performance. This underscores the 'WAIT' rating's emphasis on near-term execution, with no fundamental shift in thesis but increased urgency for monitoring Q4 margin and revenue delivery. Investors must now weigh whether Credo can navigate normalization without triggering the downside scenarios outlined in the report.